VEGF-TKI

PreclinicalSmall molecule

CCity of Hope Medical Center

VEGF-TKI is one of 56 small molecule programs targeting Kidney Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

Kidney CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

216 competitors in Kidney Cancer

#DrugCompanyPhaseTrials

Nexavar

Bayer

Phase 3

22 2

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

23 3

Avastin

BBio-Thera Solutions

Phase 3

20 4

Thalomid

Bristol-Myers Squibb

Phase 3

5 5

Afinitor

Novartis

Phase 3

5 6

Cytoxan

BBaxter Healthcare Corporation

Phase 3

10 7

Lenvima

Eisai

Phase 3

1 8

Prolia

Amgen

Phase 3

1 9

Depo-Provera

Pfizer

Phase 3

1 10

Inlyta

PPrism Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Kidney Cancer1 trial

Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor

Completed·—·N/A·NCT02944617·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VEGF-TKI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VEGF-TKI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VEGF-TKI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — City of Hope Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCity of Hope Medical Center

VEGF-TKI

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Kidney Cancer1 trial

References

Drug Info

Quick Facts

Related News